International Journal of Medical Science and Pharmaceutical Research

Background: Viral hepatitis remains a major public health concern in Iraq, with hepatitis B virus (HBV) and hepatitis C virus (HCV) constituting the predominant types. Gender-based differences in infection patterns are well recognized, with HBV more commonly reported among males and HCV among females. Understanding these variations is essential for creating effective prevention and control strategies.

Aim of the Study: To examine the epidemiological determinants of viral hepatitis infection by assessing the association between sex, age distribution, and monthly/seasonal variations in relation to HBV and HCV prevalence.

Methods: A cross-sectional study was conducted using confirmed HBV and HCV cases registered in the viral hepatitis control unit of  Bagdad Al-Karkh Health Directorate. Data were analysed using SPSS  v.26. Chi-square tests were used to assess associations between infection type and gender, age group, and month of detection at a significance level of p < 0.05.

Results: A total of 996 confirmed cases were included. Males represented 61% of all cases. The highest proportion of infections occurred in the 20-39 year age group (42%), followed by 40–60 years (27%), while only 1% were below one year of age. March had the highest detection rate (27%). Statistically significant associations were observed between infection type and sex (p = 0.024), age group (p < 0.001), and month of detection (p = 0.014).

Conclusion: The study demonstrates clear epidemiological differences in HBV and HCV distribution by gender and age in Bagdad Al-Karkh Health. HBV was more prevalent among males, whereas HCV showed a higher prevalence among females. Monthly variations in detection highlight the influence of healthcare access and seasonal screening practices.

Hepatitis B virus, Hepatitis C virus, Gender differences, Epidemiology.

1. Mahmud S, Chemaitelly H, Alaama AS, Hermez JG, Abu-Raddad LJ. Characterizing trends and associations for hepatitis C virus antibody prevalence in the Middle East and North Africa: meta-regression analyses. Sci Rep. 2022;12:20637.
2. Athamneh RY, Abudalo R, Sallam M, Alqudah A, Alquran H, Amawi KF, Abu-Harirah HA. Sub-genotypes of hepatitis C virus in the Middle East and North Africa: patterns of distribution and temporal changes. Infect Genet Evol. 2023;109:105412.
3. World Health Organization (WHO). Viral hepatitis country profiles. Geneva: WHO; 2024. Available from: https://data.who.int/dashboards/hepatitis/epidemiology
4. Tarky AM, Akram WA, Al-Naaimi AS, Omer AR. Epidemiology of viral hepatitis B and C in Iraq: a national survey, 2005–2006. Zanco J Med Sci. 2013;17(1).
5. Al-Mussa ZH, Thamair HY. The prevalence rate of hepatitis C virus in Basrah city and the common causative risk factors. Iraqi Natl J Med. 2019;1(2).
6. Khairallah ASM, Hameed MM, Mousa AH, Saleh AT. Prevalence and trends of transfusion-transmissible infections among blood donors in Basra, Iraq. BMJ Open Gastroenterol. 2023;10:e000968.
7. World Health Organization. Hepatitis A factsheet. Geneva: WHO; 2019.
8. Merzah MA, et al. Epidemiology of viral hepatitis from 2007 to 2016 in Karbala Governorate, Iraq. J Res Health Sci. 2019;19(2):e00445.
9. De E, F F. Knowledge about hepatitis B virus infection and attitudes towards hepatitis B virus vaccination among Vietnamese university students. Uppsala: Uppsala University, Department of Public Health and Caring Sciences; 2013.
10. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: WHO; 2024.
11. Stroffolini T, Stroffolini G. A historical overview on the role of hepatitis B and C viruses as aetiological factors for hepatocellular carcinoma. Cancers (Basel). 2023;15(8):2388.
12. Mayo Clinic. Hepatitis B and hepatitis C: what’s the difference? Available from: https://www.mayoclinic.org/diseases-conditions/hepatitis-b/in-depth/hepatitis-b-versus-hepatitis-c
13. World Health Organization. WHO guidelines on hepatitis B and C testing. Geneva: WHO; 2017.
14. Alavian SM, et al. Hepatitis B epidemiology and vaccination strategies. World J Gastroenterol. 2013;19(7):921–36.
15. Blach S, Zeuzem S, Manns M, Altraif I, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.
16. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.
17. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553–62.
18. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2011;18(7):459–66.
19. Fathalla M, et al. Seasonal and monthly distribution of viral hepatitis in Middle Eastern countries. J Infect Public Health. 2021;14(6):777–84.
20. Al-Hamadani A, Abdul-Latif Z. Monthly variation of viral hepatitis in Iraq. Iraqi J Med Sci. 2022;20(1):55–62.
21. Abdel-Gawad M, Nour M, El-Raey F, Nagdy H, Almansoury Y, El-Kassas M. Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis. Sci Rep. 2023;13:2499.
22. Alghamdi IG, Alghamdi RM, Alghamdi MS, Alghamdi AM, Alghamdi MI, Alghamdi ZI. Epidemiology of hepatitis B in Saudi Arabia from 2006 to 2021. Saudi J Biol Sci. 2023;30(1):233–47.